Correction: Fish oil: what the prescriber needs to know

  • Leslie G Cleland1,

    Affiliated with

    • Michael J James1Email author and

      Affiliated with

      • Susanna M Proudman1

        Affiliated with

        Arthritis Research & Therapy20068:402

        DOI: 10.1186/ar1981

        Published: 1 June 2006

        It has been brought to our attention that there were a number of typographical errors in one section of our recent article [1] published in December 2005.

        All corrections apply to the section entitled, 'Biochemical rationale; Eicosanoids: cyclo-oxygenase pathway'.

        The second paragraph should read:

        The usual substrate for the COX isozymes is the n6 LC PUFA arachidonic acid (AA; C20:4n-6). Eicosapentaenoic acid (EPA; C20:5n-3), which is present in fish oil, differs from AA only by the presence of its n3 bond (Fig. 1).

        The last sentence of the third paragraph should read:

        Thus, the net effect of fish oil is to reduce the production of proinflammatory and pro-thrombotic eicosanoids (PGE2 and TXA2, respectively) but not the vascular patency factor prostacyclin (PGI2; Fig. 2).

        Finally, the first 20-Carbon fatty acid homologue pictured in Figure 1 (C20:3 n-9) is eicosatrienoic acid, rather than oleic acid.

        Authors’ Affiliations

        Rheumatology Unit, Royal Adelaide Hospital


        1. Cleland LG, James MJ, Proudman SM: Fish oil: what the prescriber needs to know. Arthritis Research & Therapy 2006, 8:202.View Article


        © BioMed Central Ltd 2006